epelsiban: Clinical Trials

5 trials of epelsiban, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 1 terminated. 5 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 15Completed 4, Terminated 1

Follow epelsiban: new trials by email Literature Review of epelsiban trials Research Report on epelsiban

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Epelsiban Administered in Repeat Doses in Healthy Women Volunteers
Epelsiban (GSK557296), Placebo to match GSK557296 - Embryo Transfer
Phase 1CompletedGlaxoSmithKline312015-07-092018-09-13
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Epelsiban in Healthy Female Volunteers
Epelsiban - Embryo Transfer
Phase 1CompletedGlaxoSmithKline122014-12-182018-09-13
A Study to Evaluate Pharmacokinetics, Pharmacodynamics and Tissue Concentrations of Epelsiban
Epelsiban, Placebo, Oxytocin - Embryo Transfer
Phase 1TerminatedGlaxoSmithKline332014-08-282017-05-08
Study to Evaluate the Pharmacokinetics, Safety and Tolerability of GSK557296 in Healthy Women Volunteers After Single and Repeat Dosing
GSK557296 10 mg, GSK557296 150 mg, GSK557296 dose 3 - Embryo Transfer
Phase 1CompletedGlaxoSmithKline362012-08-162017-06-07
A First Time in Human Study in Healthy Male Volunteers for Compound GSK557296.
GSK557296 - Obstetric Labour, Premature, Premature Ejaculation
Phase 1CompletedGlaxoSmithKline422007-10-012012-03-19

Conditions studied

Premature Birth (1)  ·  Premature Ejaculation (1)

Sponsors

GlaxoSmithKline (5)

Countries

United States (5)

Results publications

PMID 28556598, PMID 27137713